Role and importance of biochemical markers in clinical cardiology

European Heart Journal

Volumn 25, Issue 14, 2004, Pages 1187-1196

  Panteghini, Mauro ^a  

^a SPEDALI CIVILI   (Italy)

Author keywords

Biological markers; Diagnosis; Myocardial infarction; Troponin

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; CHOLINE; CREATINE KINASE; CREATINE KINASE MB; FATTY ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; MYOGLOBIN; PHOSPHOLIPASE D; PROTEIN A; TROPONIN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOLOGY; CELL DAMAGE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DATA ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; EMERGENCY WARD; ENZYME ACTIVITY; HEART INFARCTION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART VENTRICLE HYPERTROPHY; HOSPITAL ADMISSION; HUMAN; HYPERALDOSTERONISM; INFLAMMATORY CELL; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; MORTALITY; MUSCLE CELL; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN METABOLISM; Q WAVE; REACTION TIME; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ST SEGMENT; ST SEGMENT ELEVATION; SYNCYTIOTROPHOBLAST; WORLD HEALTH ORGANIZATION;

ACUTE DISEASE; BIOLOGICAL MARKERS; CARDIOLOGY; CORONARY DISEASE; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION;

EID: 3042706302     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehj.2004.04.026     Document Type: Article

References (124)

1. Panteghini M. Acute coronary syndrome. Biochemical strategies in the troponin era. Chest. 122:2002;1428-1435
2. Clerico A. The increasing impact of laboratory medicine on clinical cardiology. Clin. Chem. Lab. Med. 41:2003;871-883
3. Collinson P.O. Early diagnosis of myocardial infarction: why measure cardiac enzymes? J. Clin. Pathol. 51:1998;2-4
4. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the management of patients with unstable angina). J. Am. Coll. Cardiol. 36:2000;970-1062
5. Bertrand M.E., Simoons M.L., Fox K.A.A., et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 23:2002;1809-1840
6. Hamm C.W., Bertrand M., Braunwald E. Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet. 358:2001;1533-1538
7. Remme W.J., Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur. Heart J. 22:2001;1527-1560
8. Alpert J, Thygesen K for the Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J 2000;21:1502-13
9. Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature. Circulation 1979;59:607-8
10. Panteghini M., Apple F.S., Christenson R.H., et al. Use of biochemical markers in acute coronary syndromes. Clin. Chem. Lab. Med. 37:1999;687-693
11. Jaffe A.S., Ravkilde J., Roberts R., et al. It's time for a change to a troponin standard. Circulation. 102:2000;1216-1220
12. Hamm C.W. Acute coronary syndromes. The diagnostic role of troponins. Thromb. Res. 103:2001;S63-S69
13. Panteghini M., Pagani F., Bonetti G. The sensitivity of cardiac markers: an evidence-based approach. Clin. Chem. Lab. Med. 37:1999;1097-1106
14. Panteghini M., Cuccia C., Pagani F., et al. Coronary angiographic findings in patients with clinical unstable angina according to cardiac troponin I and T concentrations in serum. Arch. Pathol. Lab. Med. 126:2002;448-451
15. Gupta M., Lent R.W., Kaplan E.L., et al. Serum cardiac troponin I in acute rheumatic fever. Am. J. Cardiol. 89:2002;779-782
16. Dispenzieri A., Kyle R.A., Gertz M.A., et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 361:2003;1787-1789
17. Sybrandy K.C., Cramer M.J.M., Burgersdijk C. Diagnosing cardiac contusion: old wisdom and new insights. Heart. 89:2003;458-489
18. Dworschak M., Franz M., Khazen C., et al. Mechanical trauma as the major cause of troponin T release after transvenous implantation of cardioverter/defibrillators. Cardiology. 95:2001;212-214
19. Kannankeril P.J., Pahl E., Wax D.F. Usefulness of troponin I as a marker of myocardial injury after pediatric cardiac catheterization. Am. J. Cardiol. 90:2002;1128-1132
20. Cardinale D., Sandri M.T., Martinoni A., et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J. Am. Coll. Cardiol. 36:2000;517-522
21. Sato Y., Yamada T., Taniguchi R., et al. Persistently increased serum concentrations of cardiac troponin T in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation. 103:2001;369-374
22. Horwich T.B., Patel J., MacLellan W.R., et al. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation. 108:2003;833-838
23. Wright R.S., Williams B.A., Cramner H., et al. Elevations of cardiac troponin I are associated with increased short-term mortality in noncardiac critically ill emergency department patients. Am. J. Cardiol. 90:2002;634-636
24. Ammann P., Maggiorini M., Bertel O., et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J. Am. Coll. Cardiol. 41:2003;2004-2009
25. Apple F.S., Murakami M.M., Pearce L.A., et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 106:2002;2941-2945
26. Gaze D.C., Lawson G.J., Harris A., et al. Evidence of myocyte necrosis in glycogen storage disease type II. Clin. Chem. 49(Suppl):2003;A39
27. Chance J.J., Segal J.B., Wallerson G., et al. Cardiac troponin T and C-reactive protein as markers of acute cardiac allograft rejection. Clin. Chim. Acta. 312:2001;31-39
28. Missov E., Mentzer W., Laprade M., et al. Cardiac markers of injury in hemoglobinopathy patients with transfusion hemosiderosis. J. Am. Coll. Cardiol. 37:2001;470A
29. Hamwi S.M., Sharma A.K., Weissman N.J., et al. Troponin-I elevation in patients with increased left ventricular mass. Am. J. Cardiol. 92:2003;88-90
30. Fleming S.M., O'Gorman T., Finn J., et al. Cardiac troponin I in pre-eclampsia and gestational hypertension. Br. J. Obstet. Gynaecol. 107:2000;1417-1420
31. Arlati S., Brenna S., Prencipe L., et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med. 26:2000;31-37
32. Mutch W.J., Kulkarmi U.V., Croal B.L., et al. Cardiac marker levels in hypothyroidism. Clin. Chem. 47(Suppl):2001;A199
33. Lauer B., Niederau C., Kuhl U., et al. Cardiac troponin T in patients with clinically suspected myocarditis. J. Am. Coll. Cardiol. 30:1997;1354-1359
34. Brandt R.R., Filzmaier K., Hanrath P. Circulating cardiac troponin I in acute pericarditis. Am. J. Cardiol. 87:2001;1326-1328
35. Lopez-Jimenez F., Goldman L., Sacks D.B., et al. Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data. J. Am. Coll. Cardiol. 29:1997;1241-1245
36. Giannitsis E., Muller-Bardorff M., Kurowski V., et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation. 102:2000;211-217
37. Spies C., Haude V., Fitzner R., et al. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest. 113:1998;1055-1063
38. Collinson P.O., Stubbs P.J. Are troponins confusing? Heart. 89:2003;1285-1287
39. Galvani M., Panteghini M., Ottani F., et al. The new definition of myocardial infarction: analysis of the ESC/ACC consensus document and reflections on its applicability to the Italian Health System. Ital. Heart J. 3:2002;543-557
40. Panteghini M. Recommendations on use of biochemical markers in acute coronary syndrome: IFCC proposals. eJIFCC 14. Available from http://www.ifcc.org/ejifcc/vol14no2/1402062003014n.htm
41. Jaffe A. Caveat emptor. Am. J. Med. 115:2003;241-244
42. Morrow D.A., Cannon C.P., Rifai N., et al. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 286:2001;2405-2412
43. Venge P., Lagerqvist B., Diderholm E., et al. Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease. Am. J. Cardiol. 89:2002;1035-1041
44. James S., Armstrong P., Califf R., et al. Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial. Am. J. Med. 115:2003;178-184
45. Apple F.S., Wu A.H.B. Myocardial infarction redefined: role of cardiac troponin testing. Clin. Chem. 47:2001;377-379
46. Apple F.S., Quist H.E., Doyle P.J., et al. Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin. Chem. 49:2003;1331-1336
47. Panteghini M., Pagani F., Yeo K.T.J., et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin. Chem. 50:2004;327-332
48. Apple F.S., Wu A.H., Jaffe A.S. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am. Heart J. 144:2002;981-986
49. Sheehan P., Blennerhassett J., Vasikaran S.D. Decision limit for troponin I and assay performance. Ann. Clin. Biochem. 39:2002;231-236
50. Koukkunen H., Penttilä K., Kemppainen A., et al. Differences in the diagnosis of myocardial infarction by troponin T compared with clinical and epidemiologic criteria. Am. J. Cardiol. 88:2001;727-731
51. Kontos M.C., Fritz L.M., Anderson F.P., et al. Impact of the troponin standard on the prevalence of acute myocardial infarction. Am. Heart J. 146:2003;446-452
52. Ferguson J.L., Beckett G.J., Stoddart M., et al. Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction. Heart. 88:2002;343-347
53. Panteghini M. The measurement of cardiac markers. Where should we focus? Am. J. Clin. Pathol. 118:2002;354-361
54. Apple F.S. Clinical and analytical standardization issues confronting cardiac troponin I. Clin. Chem. 45:1999;18-20
55. Panteghini M. Current concepts in standardization of cardiac marker immunoassays. Clin. Chem. Lab. Med. 42:2004;3-8
56. Panteghini M. Performance of today's cardiac troponin assays and tomorrow's. Clin. Chem. 48:2002;809-810
57. Freda B.J., Tang H.W., Van Lente F., et al. Cardiac troponins in renal insufficiency. Review and clinical implications. J. Am. Coll. Cardiol. 40:2002;2065-2071
58. Lamb E.J., Webb M.C., Abbas N.A. The significance of serum troponin T in patients with kidney disease: a review of the literature. Ann. Clin. Biochem. 41:2004;1-9
59. Diris J.H.C., Hackeng C.M., Kooman J.P., et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation. 109:2004;23-25
60. Hamm C.W. Cardiac biomarkers for rapid evaluation of chest pain. Circulation. 104:2001;1454-1456
61. Keffer J.H. The cardiac profile and proposal practice guideline for acute ischemic heart disease. Am. J. Clin. Pathol. 107:1997;398-409
62. Wu A.H.B., Apple F.S., Gibler W.B., et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases. Clin. Chem. 45:1999;1104-1121
63. O'Neil B.J., Ross M.A. Cardiac markers protocols in a chest pain observation unit. Emerg. Med. Clin. North Am. 19:2001;67-86
64. de Lemos J.A., Morrow D.A., Gibson C.M., et al. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies. J. Am. Coll. Cardiol. 40:2002;238-244
65. McCord J., Nowak R.M., Hudson M.P., et al. The prognostic significance of serial myoglobin, troponin I, and creatine kinase-MB measurements in patients evaluated in the emergency department for acute coronary syndrome. Ann. Emerg. Med. 42:2003;343-350
66. Newby L.K. The emerging role of myoglobin for risk stratification. Am. Heart J. 142:2001;4-6
67. McCord J., Nowak R.M., McCullough P.A., et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation. 104:2001;1483-1488
68. Ng S.M., Krishnaswamy P., Morissey R., et al. Ninety-minute accelerated critical pathway for chest pain evaluation. Am. J. Cardiol. 88:2001;611-617
69. Jesse R.L. Rationale for the early clinical application of markers of ischemia in patients with suspected acute coronary syndromes. Wu A.H.B. Cardiac markers. 2nd ed. 2003;245-257 Humana Press, Totowa, NJ
70. Morrow D.A., de Lemos J.A., Sabatine M.S., et al. The search for a biomarker of cardiac ischemia. Clin. Chem. 49:2003;537-539
71. Kleinfeld A.M., Prothro D., Brown D.L., et al. Increases in serum unbound free fatty acid levels following coronary angioplasty. Am. J. Cardiol. 78:1996;1350-1354
72. Kleinfeld A.M., Kleinfeld K.J., Adams J.E. Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J. Am. Coll. Cardiol. 39:2002;312A
73. Adams J.E., Kleinfeld A., Roe M., et al. Measurement of levels of unbound free fatty acid allows the early identification of patients with acute coronary syndrome. Circulation. 106(Suppl II):2002;532
74. 2+ binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia. Eur. J. Biochem. 268:2001;42-47
75. Christenson R.H., Duh S.H., Sanhai W.R., et al. Characteristics of an albumin cobalt binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin. Chem. 47:2001;464-470
76. Bar-Or D., Winkler J.V., VanBenthuysen K., et al. Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am. Heart J. 141:2001;985-991
77. Sinha M.K., Gaze D.C., Tippins J.R., et al. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation. 107:2003;2403-2405
78. Apple F.S., Quist H.E., Otto A.P., et al. Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin. Chem. 48:2002;1097-1100
79. Bhagavan N.V., Lai E.M., Rios P.A., et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin. Chem. 49:2003;581-585
80. Mulvihill N.T., Foley J.B. Inflammation in acute coronary syndromes. Heart. 87:2002;201-204
81. Blake G.J., Ridker P.M. C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J. Am. Coll. Cardiol. 41:2003;37S-42S
82. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331:1994;417-424
83. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J. Am. Coll. Cardiol. 31:1998;1460-1465
84. Heeschen C., Hamm C.W., Bruemmer J., et al. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J. Am. Coll. Cardiol. 35:2000;1535-1542
85. Lindahl B., Toss H., Siegbahn A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N. Engl. J. Med. 343:2000;1139-1147
86. Mueller C., Buettner H.J., Hodgson J.M., et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 105:2002;1412-1415
87. Kennon S., Timmis A.D., Whitbourn R., et al. C reactive protein for risk stratification in acute coronary syndromes? Verdict: unproven. Heart. 89:2003;1288-1290
88. Pearson T.A., Mensah G.A., Alexander R.W., et al. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107:2003;499-511
89. Salomon D.H., Stone P.H., Glynn R.J., et al. Use of risk stratification to identify patients with unstable angina likeliest to benefit from an invasive versus conservative management strategy. J. Am. Coll. Cardiol. 38:2001;969-976
90. Barron H.V., Cannon C.P., Murphy S.A., et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction. A Thrombolysis in Myocardial Infarction 10 substudy. Circulation. 102:2000;2329-2334
91. Cannon C.P., McCabe C.H., Wilcox R.G., et al. Association of white blood cell count with increased mortality in acute myocardial infarction and unstable angina pectoris. Am. J. Cardiol. 87:2001;636-639
92. Mueller C., Neumann F.J., Perruchoud A.P., et al. White blood cell count and long term mortality after non-ST elevation acute coronary syndrome treated with very early revascularization. Heart. 89:2003;389-392
93. Henn V., Slupsky J.R., Gräfe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:1998;591-594
94. André P., Nannizzi-Alaimo L., Prasad S.K., et al. Platelet-derived CD40L. The switch-hitting player of cardiovascular disease. Circulation. 106:2002;896-899
95. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N. Engl. J. Med. 348:2003;1104-1111
96. Varo N., de Lemos J.A., Libby P., et al. Soluble CD40L. Risk prediction after acute coronary syndromes. Circulation. 108:2003;1049-1052
97. Eiserich J.P., Baldus S., Brennan M.L., et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 296:2002;2391-2394
98. Brennan M.L., Penn M.S., Van Lente F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N. Engl. J. Med. 349:2003;1595-1604
99. Baldus S., Heeschen C., Meinertz T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 108:2003;1440-1445
100. Szmitko P.E., Wang C.H., Weisel R.D., et al. New markers of inflammation and endothelial cell activation. Part I. Circulation. 108:2003;1917-1923
101. Cipollone F., Marini M., Fazia M., et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler. Thromb. Vasc. Biol. 21:2001;327-334
102. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 107:2003;690-695
103. Rabbani L.E. Acute coronary syndromes - beyond myocyte necrosis. N. Engl. J. Med. 345:2001;1057-1059
104. Wu A.H.B., Crosby P., Fagan G., et al. Ischemia-modified albumin, free fatty acids, whole blood choline, B-type natriuretic peptide, glycogen phosphorylase BB, and cardiac troponin. Wu A.H.B. Cardiac markers. 2nd ed. 2003;259-277 Humana Press, Totowa, NJ
105. Danne O., Möckel M., Lueders C., et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am. J. Cardiol. 91:2003;1060-1067
106. Lawrence J.B., Oxvig C., Overgaard M.T., et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc. Natl. Acad. Sci. USA. 96:1999;3149-3153
107. Bayes-Genis A., Conover C.A., Overgaard M.T., et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N. Engl. J. Med. 345:2001;1022-1029
108. Lund J., Qin Q.P., Ilva T., et al. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 108:2003;1924-1926
109. Qin Q.P., Laitinen P., Majamaa-Voltti K., et al. Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand. Cardiovasc. J. 36:2002;358-361
110. Oxvig C., Sand O., Kristensen T., et al. Circulating human pregnancy-associated plasma protein-A is disulfide-bridged to the proform of eosinophil major basic protein. J. Biol. Chem. 268:1993;12243-12246
111. Khosravi J., Diamandi A., Krishna R.G., et al. Pregnancy associated plasma protein-A: ultrasensitive immunoassay and determination in coronary heart disease. Clin. Biochem. 35:2002;531-538
112. Cowie M.R., Mendez G.F. BNP and congestive heart failure. Progr. Cardiovasc. Dis. 44:2002;293-321
113. Clerico A. Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: are they merely markers of cardiac disease? Clin. Chem. Lab. Med. 40:2002;752-760
114. Kay J.D., Trichon B.H., Kisslo K., et al. Serum brain natriuretic peptide levels cannot differentiate pulmonary disease from left-heart failure if the right ventricle is dilated. Circulation. 108:2003;IV-397
115. Clerico A., Iervasi G., Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm. Metab. Res. 31:1999;487-498
116. Struthers A.D. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart. 87:2002;97-98
117. Struthers A.D. How to use natriuretic peptide levels for diagnosis and prognosis. Eur. Heart J. 20:1999;1374-1375
118. Cowie M.R., Jourdain P., Maisel A., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur. Heart J. 24:2003;1710-1718
119. de Lemos J.A., Morrow D.A. Brain natriuretic peptide measurement in acute coronary syndromes. Ready for clinical application? Circulation. 106:2002;2868-2870
120. White H.D., French J.K. Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. J. Am. Coll. Cardiol. 42:2003;1917-1920
121. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 350:2004;655-663
122. Packer M.P. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Circulation. 108:2003;2950-2953
123. Karmen A., Wroblewski F., LaDue J.S. Transaminase activity in human blood. J. Clin. Invest. 34:1955;126-133
124. Morrow D.A., Braunwald E. Future of biomarkers in acute coronary syndromes. Moving toward a multimarker strategy. Circulation. 108:2003;250-252